The global Anal Fissure Treatment Market is estimated to be valued at US$ 1,039.3 Mn in 2023 and is expected to exhibit a CAGR of 5.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
An anal fissure is a tear or cut in the skin of anal canal. It causes pain and bleeding during and after bowel movements. Anal fissures are most commonly caused by constipation and hard stools. Treatment of anal fissures involves the use of topical drugs such as nitrates, calcium channel blockers and botulinum toxins. The key objective of anal fissure treatment is to relieve pain, reduce spasms of internal sphincter muscle and promote healing of anal fissure. These treatment options aim to prevent reoccurrence of anal fissure and provide long term relief from associated symptoms.
Market key trends:
Rising prevalence of anal fissures due to lifestyle changes and unhealthy dietary habits is a key factor driving the growth of this market. According to the American Society of Colon and Rectal Surgeons (ASCRS), nearly 25% of adults experience anal fissures at some point in their lifetime. Rapid adoption of medical technologies and advancement in treatment options is also boosting the market growth. Key players are focusing on developing new topical drugs and combination therapies to provide more effective relief from anal fissures. For instance, in 2021, AstraZeneca received FDA approval for a new combination drug, SYNBIOTIC, containing sodium nitroprusside and lidocaine for topical treatment of chronic anal fissures. Increasing awareness regarding anal fissure treatment options among patients and healthcare providers through promotional activities by industry players will further contribute to market expansion over the forecast period.
Threat of new entrants: Low-costs barriers are driving threats of new entrants in the anal fissure treatment market. Bargaining power of buyers: The number of buyers is large due to increasing incidence of anal fissures globally. Bargaining power of suppliers: Suppliers have moderate bargaining power due to availability of substitute treatment options. Threat of new substitutes: Substitutes including new surgical and non-surgical procedures can pose threat to existing treatment methods. Competitive rivalry: Intense competition exists between key players offering generic and branded drugs.
The Global Anal Fissure Treatment Market Size is expected to witness high growth, exhibiting CAGR of 5.3% over the forecast period, due to increasing incidence of anal fissures among adults and pediatric population.
North America is expected to dominate the global anal fissure treatment market during the forecast period. This is attributed to growing prevalence of anal fissures and increasing awareness regarding its treatment options in the region. Asia Pacific market is anticipated to exhibit fastest growth owing to rising disposable income and healthcare spending.
Key players operating in the anal fissure treatment market are Allergan, Novartis, Pfizer, Takeda Pharmaceutical Company, Cook Medical, Medtronic, Johnson & Johnson, AstraZeneca, GlaxoSmithKline, Sanofi, Merck, Abbott Laboratories, Bayer, Astellas Pharma, Aurobindo Pharma, Ferring Pharmaceuticals, Salix Pharmaceuticals, Eli Lilly, Bristol-Myers Squibb, Boehringer Ingelheim.
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it